Description:
The purpose of this study is to evaluate whether the efficacy of JNJ-757 combined with
nivolumab is better than the efficacy of nivolumab monotherapy for participants with
mesothelin-positive relapsed/refractory Stage IIIB or Stage IV adenocarcinoma of the lung.
The open-label study comprises of two parts i.e. Phase 1b (safety run-in) and Phase 2.
Phase1b consists of 1 arm whereas Phase 2 is randomized into 2 groups i.e. Group A and Group
B.
Title
- Brief Title: An Efficacy and Safety Study of JNJ-64041757, a Live Attenuated Listeria Monocytogenes Immunotherapy, in Combination With Nivolumab Versus Nivolumab Monotherapy in Participants With Advanced Adenocarcinoma of the Lung
- Official Title: An Open-Label Randomized Phase 1b/2 Study of the Efficacy and Safety of JNJ-64041757, a Live Attenuated Listeria Monocytogenes Immunotherapy, in Combination With Nivolumab Versus Nivolumab Monotherapy in Subjects With Advanced Adenocarcinoma of the Lung
Clinical Trial IDs
- ORG STUDY ID:
CR108232
- SECONDARY ID:
2016-002543-41
- SECONDARY ID:
64041757LUC2002
- NCT ID:
NCT03371381
Conditions
Interventions
| Drug | Synonyms | Arms |
|---|
| JNJ-64041757 | JNJ-757 | Nivolumab + JNJ-64041757 |
| Nivolumab | | Nivolumab |
Purpose
The purpose of this study is to evaluate whether the efficacy of JNJ-757 combined with
nivolumab is better than the efficacy of nivolumab monotherapy for participants with
mesothelin-positive relapsed/refractory Stage IIIB or Stage IV adenocarcinoma of the lung.
The open-label study comprises of two parts i.e. Phase 1b (safety run-in) and Phase 2.
Phase1b consists of 1 arm whereas Phase 2 is randomized into 2 groups i.e. Group A and Group
B.
Detailed Description
This study evaluates safety and efficacy of JNJ-64041757 with nivolumab. The total study
duration will be up to 3 years. It will consist of safety run-in and randomized phase which
will comprise of Screening phase(Day(D) -28 to D -1),Treatment Phase,End of Adverse Event
Evaluation Period (100 D after last dose of nivolumab)and Post-treatment Follow-up
Phase(Every 3 Months). The primary hypothesis is that addition of JNJ-640417577 to nivolumab
will result in higher objective response rate compared with nivolumab monotherapy in at least
one of programmed death receptor ligand 1 subgroups in participants with relapsed or
refractory StageIIIB or StageIV adenocarcinoma of lung. The study procedures include blood
culture bacterial shedding assessments, pharmacokinetics, immunogenicity, and biomarkers.
Safety will be monitored throughout study.
Trial Arms
| Name | Type | Description | Interventions |
|---|
| Nivolumab + JNJ-64041757 | Experimental | Phase 1b and Phase 2 Group A/Arm 1: Participants will receive separate intravenous (IV) infusions of nivolumab and JNJ-64041757 over approximately 60 minutes during each treatment cycle until disease progression, unacceptable toxicity, protocol violation requiring discontinuation of study treatment, withdrawal of consent, noncompliance with study procedures, or the sponsor terminates the study. | |
| Nivolumab | Active Comparator | Phase 2 Group B/Arm 2: Participants will receive intravenous (IV) infusions of nivolumab over approximately 60 minutes during each treatment cycle until disease progression, unacceptable toxicity, protocol violation requiring discontinuation of study treatment, withdrawal of consent, noncompliance with study procedures, or the sponsor terminates the study. | |
Eligibility Criteria
Inclusion Criteria:
- Disease-related criteria: Histologically documented adenocarcinoma of the lung; Stage
IIIB or Stage IV disease; Biopsy material available for central assessment of
programmed death receptor ligand 1 (PD-L1) and mesothelin
- Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
- Progressive disease during or after platinum-based doublet chemotherapy
- A woman of childbearing potential must have a negative serum or urine pregnancy test
within 14 days before the first dose of nivolumab
- Willing and able to adhere to the prohibitions and restrictions specified in this
protocol
Exclusion Criteria:
- Tumor with activating epidermal growth factor receptor (EGFR) mutation or ALK
translocation
- More than 1 prior line of chemotherapy for metastatic disease (Phase 2)
- History of disallowed therapies, as follows: In Phase 1b only: Prior exposure to
anti-programmed death receptor-1(PD1), anti programmed death receptor ligand 1
(PD-L1), anti-programmed death receptor ligand 2 (PD-L2), anti-CD137, or
anti-cytotoxic T lymphocyte associated antigen 4 (CTLA-4) antibody within 28 days
before the first dose of study agent, In Phase 2 only: Prior exposure to anti-PD1,
anti PD-L1, anti-PD-L2, anti-CD137, or anti-cytotoxic T lymphocyte associated antigen
4 (CTLA-4) antibody, History of listeriosis or vaccination with a Listeria-based
vaccine or prophylactic vaccine within 28 days before the first dose of study agent,
Chemotherapy within 28 days before the first dose of study agent, Radiation within 14
days before the first dose of study agent
- History of any other condition that may require the initiation of anti-tumor necrosis
factor alpha (TNF alpha) therapies or other immunosuppressant medications during the
study
- Active second malignancy within 2 years prior to Cycle 1 Day 1 (Phase 1b) or
randomization (Phase 2)
| Maximum Eligible Age: | N/A |
| Minimum Eligible Age: | 18 Years |
| Eligible Gender: | All |
| Healthy Volunteers: | No |
Primary Outcome Measures
| Measure: | Phase 1b: Percentage of Participants With Objective Response |
| Time Frame: | Up to 6.8 Months |
| Safety Issue: | |
| Description: | Objective response rate was defined as the percentage of participants who achieved a complete response (CR) or partial response (PR) according to Response Evaluation Criteria in Solid Tumors, Version 1.1 (RECIST). RECIST for CR - disappearance of all lesions; all lymph nodes were non-pathological in size and normalization of tumor marker level; PR - greater than or equal to (>=) 30 percent (%) decrease in the sum of the diameters of all target lesions compared with baseline, in absence of new lesions or unequivocal progression of nontarget lesions. |
Secondary Outcome Measures
| Measure: | Phase 1b: Duration of Objective Response (DOR) |
| Time Frame: | Up to 6.8 months |
| Safety Issue: | |
| Description: | Duration of objective response was defined as the time from initial documentation of a response (CR or PR) to first documented date of disease progression (PD) or death from any cause. RECIST for PD - sum of diameters had increased by >= 20% and >=5 mm from nadir (including baseline if it was smallest sum). Participants with measurable disease: for "unequivocal progression" based on non-target disease, there was an overall level of substantial worsening that merits discontinuation of therapy (if target disease is stable disease [SD]/PR). Participants without measurable disease: for "unequivocal progression" of non-target disease, increase in overall tumor burden must be comparable to increase required for PD of measurable disease. Furthermore, appearance of 1 or more new lesions or unequivocal progression of a non-target lesion. |
| Measure: | Phase 1b: Number of Participants With Progression-free Survival (PFS) Event (Progressed or Died Before Progression) |
| Time Frame: | Up to 6.8 months |
| Safety Issue: | |
| Description: | Number of participants with PFS event (progressed or died before progression) were reported. PFS - time from date of randomization until date of first documented evidence of PD (or relapse for participants who experience CR during study) or death from any cause, whichever comes first. RECIST for PD - sum of diameters had increased by >= 20% and >=5 mm from nadir (including baseline if it was smallest sum). Participants with measurable disease: for "unequivocal progression" based on non-target disease, there was an overall level of substantial worsening that merits discontinuation of therapy (if target disease is SD/PR). Participants without measurable disease: for "unequivocal progression" of non-target disease, increase in overall tumor burden must be comparable to increase required for PD of measurable disease. Furthermore, appearance of 1 or more new lesions or unequivocal progression of a non-target lesion. |
| Measure: | Phase 1b: Number of Participants With Overall Survival (OS) Event (Died) |
| Time Frame: | Up to 6.8 months |
| Safety Issue: | |
| Description: | Number of participants with OS event (died) were reported. Overall Survival was defined as the duration from the date of randomization to the date of participant's death due to any cause. |
| Measure: | Phase 1b: Number of Participants With Treatment Emergent Adverse Events (TEAEs) |
| Time Frame: | Up to 6.8 months |
| Safety Issue: | |
| Description: | An adverse event is any untoward medical event that occurs in a participant administered an investigational product and it does not necessarily indicate only events with clear causal relationship with the relevant investigational product. TEAEs are defined as adverse events with onset or worsening on or after date of first dose of study treatment. |
| Measure: | Phase 1b: Number of Participants With Positive Blood Culture |
| Time Frame: | Up to 6.8 months |
| Safety Issue: | |
| Description: | Number of participants with surveillance cultures positive for listeriosis were reported. |
| Measure: | Phase 1b: Number of Participants With Bacterial Shedding |
| Time Frame: | Up to 6.8 months |
| Safety Issue: | |
| Description: | Number of participants with bacterial shedding were reported. The shedding of JNJ-64041757 was studied in feces by stool or rectal swab, urine and saliva. |
| Measure: | Phase 1b: Serum Concentrations of Nivolumab |
| Time Frame: | Up to 6.8 months |
| Safety Issue: | |
| Description: | Nivolumab serum concentrations were reported. |
| Measure: | Phase 1b: Number of Participants With Anti-nivolumab Antibodies |
| Time Frame: | Up to 6.8 months |
| Safety Issue: | |
| Description: | Number of participants with antibodies to nivolumab were reported. |
Details
| Phase: | Phase 1/Phase 2 |
| Primary Purpose: | Interventional |
| Overall Status: | Terminated |
| Lead Sponsor: | Janssen Research & Development, LLC |
Last Updated
December 11, 2019
